AmCad BioMed Bilan de santé

Santé financière contrôle des critères 6/6

AmCad BioMed possède un total de capitaux propres de NT$451.6M et une dette totale de NT$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont NT$481.3M et de NT$29.8M.

Informations clés

Ratio d'endettement

NT$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	NT$257.10m
Fonds propres	NT$451.55m
Total du passif	NT$29.78m
Total des actifs	NT$481.33m

Mises à jour récentes de la santé financière

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Apr 19

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Jan 04

Recent updates

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Apr 19

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Jan 04

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4188 ( NT$298.5M ) dépassent ses passifs à court terme ( NT$21.3M ).

Passif à long terme: Les actifs à court terme de 4188 ( NT$298.5M ) dépassent ses passifs à long terme ( NT$8.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4188 est sans dette.

Réduire la dette: 4188 n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 4188 dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 4188 dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de croître à un taux historique de 20 % chaque année

AmCad BioMed Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Recent updates

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: NT$0.19 loss per share (vs NT$0.24 loss in 2Q 2023)

AmCad BioMed Corporation Announces Change of the Corporate Governance Officer

AmCad BioMed Corporation to Report Q2, 2024 Results on Aug 08, 2024

AmCad BioMed Corporation has completed a Follow-on Equity Offering in the amount of TWD 230 million.

First quarter 2024 earnings released: NT$0.29 loss per share (vs NT$0.20 loss in 1Q 2023)

AmCad BioMed Corporation has filed a Follow-on Equity Offering in the amount of TWD 350 million.

AmCad BioMed Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$0.85 loss per share (vs NT$1.01 loss in FY 2022)

AmCad BioMed Corporation, Annual General Meeting, Jun 26, 2024

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: NT$0.24 loss per share (vs NT$0.22 loss in 2Q 2022)

New minor risk - Share price stability

AmCad BioMed Corporation Announces Management Changes

AmCad Biomed Corporation Appoints Maureen Chang as Corporate Governance Officer

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.27 loss per share (vs NT$0.001 profit in 3Q 2021)

Second quarter 2022 earnings released: NT$0.22 loss per share (vs NT$0.16 loss in 2Q 2021)

First quarter 2022 earnings released: NT$0.15 loss per share (vs NT$0.21 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

AmCad BioMed Corporation Appoints Maureen Chang as Spokesperson, Financial Officer and Accounting Officer

Third quarter 2021 earnings released: EPS NT$0.001 (vs NT$0.18 loss in 3Q 2020)

AmCad BioMed Corporation Announces Receiving FDA Approval of AmCad UTdeep Learning Advanced Version

Second quarter 2021 earnings released: NT$0.16 loss per share (vs NT$0.10 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.21 loss per share (vs NT$0.30 loss in 1Q 2020)

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

AmCad BioMed Corporation, Annual General Meeting, May 21, 2021

New 90-day low: NT$18.55

New 90-day low: NT$18.80

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Third quarter 2020 earnings released: NT$0.19 loss per share

AmCad BioMed Corporation Announces Board Changes

AmCad BioMed Corporation Announces Resignation of Lee, Chen Chia as Chairperson, Effective November 5, 2020

New 90-day low: NT$19.45

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines